Vascular Cognitive Impairment and Vascular Dementia

Vascular cognitive impairment (VCI) is an umbrella term describing cognitive deficits attributable to cerebrovascular pathology. It ranges from mild vascular cognitive impairment no dementia (VCI-ND) through to vascular dementia (VaD), the second most common cause of dementia after Alzheimer disease (AD) worldwide. In clinical practice, mixed Alzheimer-vascular pathology is more frequent than either entity alone, particularly in adults over 75 years of age.

The hallmark cognitive profile of VCI differs from AD: executive dysfunction (planning, set-shifting, working memory), psychomotor slowing and impaired attention typically predominate, while episodic memory may be relatively preserved until later stages. Associated neurological signs — gait disturbance (marche à petits pas), pseudobulbar affect, urinary urgency and focal reflex asymmetry — reflect the underlying white-matter and subcortical disease burden.

Australian Burden

• Dementia affects an estimated 421,000 Australians (2024 AIHW), with vascular and mixed-vascular subtypes accounting for 15–20 % of cases and contributing to a further 30–40 % as a co-pathology.
• Stroke is the third leading cause of death in Australia (~8,200 deaths/year) and a leading cause of disability; approximately 25–30 % of stroke survivors develop post-stroke dementia within 5 years.
• White-matter hyperintensities are present on MRI in > 70 % of Australians aged over 75, indicating a high population prevalence of subclinical cerebral small vessel disease.
• Total direct and indirect cost of dementia in Australia exceeds billion annually (Dementia Australia, 2024).
• Aboriginal and Torres Strait Islander Australians have stroke incidence rates 2.4 times higher than non-Indigenous Australians (AIHW 2023), with onset approximately 10 years younger and a correspondingly higher burden of early-onset VCI.

Vascular brain injury results from any mechanism that reduces cerebral perfusion or damages brain parenchyma through vascular mechanisms. The principal pathological substrates include:

In most patients, multiple pathological mechanisms coexist. The concept of "total vascular burden" — aggregating WMH volume, lacunar count, microbleeds and cortical infarcts — correlates more strongly with cognitive decline than any single lesion type. Amyloid-β deposition (as in mixed AD-vascular pathology) further lowers the threshold for clinical expression of vascular injury.

Cerebral small vessel disease (SVD) is the most common cause of VCI worldwide and the principal substrate of vascular contributions to cognitive impairment in Australian older adults. It is a progressive, insidious condition driven primarily by chronic hypertension, diabetes mellitus and ageing.

Radiological Markers of SVD

Clinical Features of SVD-Related VCI

• Insidious onset with slow, stepwise or gradual decline (distinct from the acute stepwise pattern of large-vessel stroke).
• Executive dysfunction — impaired Trail-Making Test B, reduced verbal fluency, poor dual-task performance.
• Psychomotor slowing — increased reaction time, bradyphrenia.
• Gait disturbance — short stride, widened base, increased fall risk; "vascular parkinsonism" in severe cases.
• Urinary urgency and frequency (disruption of frontal-subcortical circuits).
• Mood disturbance — apathy (more common than depression in pure SVD), emotional lability.
• Relatively preserved episodic memory until late stages (verbal recall may be normal if retrieval cues are provided).

Strategic Infarct Dementia

Strategic infarct dementia occurs when a relatively small stroke disrupts a critical cognitive hub. The resultant deficit can be disproportionate to the volume of infarcted tissue. Key strategic locations include:

Post-Stroke Dementia

Post-stroke dementia (PSD) is defined as any dementia occurring after a clinically evident stroke, typically within 6–12 months. It is classified as early (within the first year) or late (beyond one year). Risk factors for PSD include:

• Pre-existing cognitive decline or mild cognitive impairment (strongest predictor).
• Stroke severity (NIHSS ≥ 12) and large-territory infarction.
• Recurrent stroke — each event increases dementia risk approximately 2-fold.
• Atrial fibrillation — cardioembolic strokes are larger and more likely to cause dementia.
• Pre-existing white-matter disease (the "total vascular burden" threshold model).
• Diabetes mellitus, hyperhomocysteinaemia and low education level (cognitive reserve).
• Haemorrhagic transformation and posterior-circulation strokes.

Mixed Alzheimer-vascular dementia (mixed AD-VaD) is the most common pathological combination in older adults and is the dominant clinical entity in Australian dementia practice. Autopsy series consistently demonstrate that pure AD or pure VaD pathology is present in fewer than half of dementia cases; the majority show co-occurring pathologies.

Pathological Overlap

• Amyloid-β plaques and tau neurofibrillary tangles (Alzheimer pathology) frequently coexist with ischaemic white-matter lesions, lacunes and microinfarcts.
• Vascular risk factors (hypertension, diabetes, dyslipidaemia, smoking) accelerate both atherosclerosis and amyloid-β deposition, creating shared risk pathways.
• Hypoperfusion impairs amyloid-β clearance via perivascular (glymphatic) drainage, while Alzheimer-related endothelial dysfunction worsens cerebral blood-flow autoregulation — a bidirectional "vicious cycle."
• The threshold model posits that neither pathology alone exceeds the dementia threshold in many patients; the combination does.

Clinical Features Suggesting Mixed AD-VaD

Core Clinical Features

The clinical phenotype of VCI is heterogeneous but several features help distinguish it from primary neurodegenerative dementias:

• Executive dysfunction — difficulty planning, organising, multitasking, set-shifting (Trail-Making B errors), and poor working memory.
• Psychomotor slowing — bradyphrenia, reduced spontaneous speech, increased latency in responses.
• Attention deficits — impaired sustained and divided attention; fluctuating cognition may mimic delirium or dementia with Lewy bodies.
• Gait disturbance — small-stepped, wide-based, magnetic gait; increased fall risk; often precedes cognitive complaints.
• Urinary symptoms — urgency, frequency, incontinence (frontal-subcortical disconnection).
• Mood and behaviour — apathy (the most common behavioural symptom), depression, emotional lability (pseudobulbar affect).
• Relatively preserved — visuospatial skills, praxis and language naming until late stages (unless dominant-hemisphere cortical infarct).

Diagnostic Criteria

No single diagnostic criterion set has achieved universal acceptance. The most widely used frameworks include:

Differential Diagnosis

• Alzheimer disease (amnestic presentation, insidious course, no focal signs).
• Dementia with Lewy bodies (visual hallucinations, fluctuating cognition, parkinsonism — may overlap with vascular parkinsonism).
• Normal-pressure hydrocephalus (wet, wobbly, wacky triad — assessable with CSF tap test; reversible with VP shunt).
• Delirium — acute onset, fluctuating course, attentional impairment; always exclude in acute/subacute presentations (confusion assessment method, CAM).
• Depression — pseudodementia; cognitive complaints out of proportion to objective testing; prominent mood symptoms.
• Frontotemporal dementia — early behavioural/personality change, disinhibition, progressive aphasia; imaging shows frontal/temporal atrophy.
• Chronic subdural haematoma — subacute cognitive decline with headache; recent falls or anticoagulant use; treatable with surgical evacuation.

Investigation of suspected VCI serves three purposes: (1) confirming vascular pathology and excluding treatable mimics, (2) identifying vascular risk factors, and (3) assessing the contribution of concomitant Alzheimer pathology when clinically indicated.

Laboratory Investigations

Neuroimaging

Cognitive Assessment Tools

Cardiovascular Investigations

Vascular risk-factor modification is the most evidence-based and impactful intervention for VCI. Unlike neurodegenerative pathology, vascular injury is amenable to prevention and, in some cases, partial reversal. The Australian Stroke Foundation (2023) and National Stroke Guidelines (2024) recommend the following targets:

Blood Pressure

• First-line agents: ACE inhibitor/ARB + thiazide-like diuretic (indapamide 1.5 mg SR OD) ± calcium-channel blocker (amlodipine 5–10 mg OD).
• Perindopril/indapamide combination (Coveram® or generics) — PBS General Benefit; preferred in PROGRESS trial population.
• Home BP monitoring recommended; ambulatory BP monitoring (MBS item 11608) for white-coat or masked hypertension.

Antiplatelet and Anticoagulant Therapy

Lipid-Lowering Therapy

• High-intensity statin for all patients with ischaemic stroke/TIA regardless of baseline LDL-C: atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily.
• LDL-C target < 1.8 mmol/L (absolute CV risk > 10 %) or < 1.4 mmol/L (very high risk, recurrent events).
• Add ezetimibe 10 mg OD (PBS General Benefit) if target not achieved; consider PCSK9 inhibitors (evolocumab, alirocumab — PBS Authority Required) for refractory cases.

Glycaemic Control

• HbA1c target < 53 mmol/mol (7.0 %) for most; individualise for frailty and hypoglycaemia risk (< 64 mmol/mol / 8.0 % if high fall risk).
• Metformin (PBS General Benefit) remains first-line; add SGLT2 inhibitors (empagliflozin, dapagliflozin — PBS Authority) or GLP-1 agonists (semaglutide, liraglutide — PBS Authority) for additional cardiovascular and renal benefit.

Lifestyle Modifications

Carotid Revascularisation

• Carotid endarterectomy (CEA) for symptomatic carotid stenosis ≥ 70 % (NASCET method) — MBS item 33568; best outcomes when performed within 14 days of TIA/minor stroke.
• Carotid artery stenting (CAS) — MBS item 33573; alternative when CEA is technically difficult (high bifurcation, contralateral occlusion, post-radiation stenosis).
• Asymptomatic carotid stenosis — consider CEA if stenosis ≥ 80 % with low surgical risk; optimal medical therapy alone is increasingly advocated (CREST-2 trial ongoing).

While risk-factor modification is the primary disease-modifying strategy, pharmacotherapy targeting cognitive symptoms provides modest benefit in VaD and mixed dementia. These agents should be considered in addition to — not instead of — vascular risk-factor control.

Agents NOT Recommended

• Nimodipine — no consistent evidence of cognitive benefit in VCI; not listed on the Australian PBS for this indication.
• Ginkgo biloba — the GEM trial showed no benefit; risk of bleeding with concurrent anticoagulation/antiplatelet therapy.
• High-dose B vitamins (B6, B12, folate) — VITATOPS trial showed no significant reduction in recurrent stroke or cognitive decline despite homocysteine lowering. Supplementation for deficiency only.
• Cerebrolysin — available in some countries but not TGA-registered in Australia; insufficient evidence.

Cognitive Monitoring

Medication Safety Monitoring

• Cholinesterase inhibitors: Check pulse rate at each visit (risk of bradycardia, syncope). LFTs at baseline; repeat if GI symptoms. ECG if history of cardiac conduction disease.
• Anticoagulants: eGFR every 6 months (dose adjustments for DOACs at eGFR < 30). Annual liver function. HAS-BLED reassessment. Faecal occult blood test if iron-deficiency anaemia develops.
• Statins: LFTs at baseline and if symptoms of myopathy. CK if muscle pain. HbA1c monitoring (small risk of new-onset diabetes).
• Antihypertensives: Postural blood pressure (lying/standing) — target no more than 20 mmHg drop systolic. Electrolytes if on ACE inhibitor/ARB + diuretic.

Driving Assessment

Cognitive Rehabilitation and Stimulation

• Cognitive rehabilitation — individualised, goal-oriented therapy delivered by an occupational therapist or neuropsychologist; targets specific executive and memory deficits using compensatory strategies (diaries, electronic prompts, routines).
• Cognitive stimulation therapy (CST) — group-based programme (14 sessions over 7 weeks); evidence-based in dementia; available at many Dementia Australia community centres.
• Computerised cognitive training — limited evidence for sustained benefit; may provide short-term improvements in attention and processing speed.

Structured Exercise

• Multimodal exercise (aerobic + resistance + balance) for ≥ 150 min/week reduces vascular risk factors and may slow cognitive decline (FINGER trial model adapted in Australia as "AU-FINGERS" study).
• Fall-prevention programmes — physiotherapy-led balance training (Otago programme, subsidised under Medicare Chronic Disease Management plans with GP Team Care Arrangements, MBS item 721/723).
• Allied health referral under Medicare CDM: up to 5 individual + group allied health services per calendar year (MBS item 10950–10970).

Carer Support and Advance Care Planning

• Carer education — Dementia Australia (1800 100 500) provides counselling, education programmes (e.g., CARERS), and support groups.
• Respite care — Commonwealth Home Support Programme (CHSP) and Home Care Packages (Level 1–4) via My Aged Care (1800 200 422).
• ACAT referral for residential aged-care when home-based care is no longer sustainable.
• Advance care planning — initiate early in the disease course while decision-making capacity is preserved. Use state-specific advance care directive forms. Document substitute decision-maker.
• Financial and legal — encourage Enduring Power of Attorney and Enduring Guardianship documentation.

Multidisciplinary Team

1. 1. Skrobot OA, O'Brien J, Black S, et al. The Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement. 2017;13(6):624-633. doi:10.1016/j.jalz.2016.10.007
2. 2. Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-218. doi:10.1097/WAD.0000000000000034
3. 3. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672-2713. doi:10.1161/STR.0b013e3182299496
4. 4. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8(11):1006-1018. doi:10.1016/S1474-4422(09)70236-4
5. 5. Stroke Foundation (Australia). Clinical Guidelines for Stroke Management 2023. Melbourne: Stroke Foundation; 2023. Available at: https://informme.org.au
6. 6. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand (CSANZ). Guideline for the diagnosis and management of hypertension in adults — 2023. Med J Aust. 2023;219(10):478-491.
7. 7. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-1041. doi:10.1016/S0140-6736(01)06178-5
8. 8. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE). N Engl J Med. 2011;365(11):981-992. doi:10.1056/NEJMoa1107039
9. 9. Black S, Román GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34(10):2323-2330. doi:10.1161/01.STR.0000091351.88566.E7
10. 10. Orgogozo JM, Rigaud AS, Stöffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33(7):1834-1839. doi:10.1161/01.STR.0000020092.24385.E7
11. 11. Australian Institute of Health and Welfare (AIHW). Dementia in Australia. Cat. no. DEM 1. Canberra: AIHW; 2024.
12. 12. Ai T, Engel O, Planas AM. Neuroprotection after vascular cognitive impairment: is there a role for cognitive rehabilitation? Front Neurol. 2021;12:694057. doi:10.3389/fneur.2021.694057
13. 13. VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol. 2010;9(9):855-865. doi:10.1016/S1474-4422(10)70187-3
14. 14. Dementia Australia. National Dementia Helpline. 1800 100 500. Available at: https://www.dementia.org.au
15. 15. Smith K, Flicker L, Lautenschlager NT, et al. High prevalence of dementia and cognitive impairment in Indigenous Australians. Neurology. 2008;71(19):1470-1473. doi:10.1212/01.wnl.0000320508.11013.4b
16. 16. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255-2263. doi:10.1016/S0140-6736(15)60461-5